---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-126268"
form_type: "8-K"
ticker: "NPCE"
cik: "0001528287"
company_name: "NeuroPace Inc"
filed_at: "2025-05-27T23:59:59+00:00"
generated_at: "2026-05-20T10:33:36.445402+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NeuroPace NAUTILUS study meets safety endpoint; primary efficacy miss but significant in subgroup

## Summary
- Primary safety endpoint met: low rate of serious adverse events related to device/implant procedure.
- Primary efficacy endpoint (time to second GTC seizure) not statistically significant in overall population.
- Statistically significant response in subgroup with lower baseline GTC seizure frequency, representing majority of participants.
- Secondary metrics (median seizure reduction, responder rates, seizure-free days) showed clinically meaningful improvements.
- Full-year 2025 financial guidance reaffirmed; CEO notes base business growing >20% YoY.

## SEC filing metadata
- accession: 0001193125-25-126268
- form_type: 8-K
- ticker: NPCE
- cik: 0001528287
- company_name: NeuroPace Inc
- filed_at: 2025-05-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528287/000119312525126268/0001193125-25-126268-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528287/000119312525126268/d909963d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-126268
- JSON: https://secwatch.observer/filing/0001193125-25-126268.json
- Plain text: https://secwatch.observer/filing/0001193125-25-126268.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.